Boosting CAR T-Cell Therapy to Combat Ovarian Cancer

Ovarian Cancer‘s Tricky Defense: How Scientists are Turning the Tables on a Deadly Foe

Ovarian cancer, notorious for its resistance to treatments, is a formidable opponent. But scientists are closing in, leveraging the power of the immune system to tackle even metastatic forms of the disease. A recent discovery by researchers at Weill Cornell Medicine has uncovered a new strategy to disrupt cancer’s mischievous tactics.

The immune system’s soldiers, T cells, often find themselves outmatched in ovarian cancer’s presence. "It’s like the T cells are in a hostile environment," explains Roddy O’Connor, an immunologist at the University of Pennsylvania. They lose their usual power to rally a strong immune response or destroy cancerous cells.

Weill Cornell Medicine researchers have now found why. A molecular pathway responsible for fat trafficking in T cells goes awry during ovarian cancer. This-Seine leads to impaired fat uptake in T cells, hampering their ability to combat the disease.

Tracking down the culprit, the team discovered that a protein called transgelin 2 (TAGLN2) is heavily suppressed in T cells from ovarian tumors. This protein, they found, plays a crucial role in lipid uptake together with another protein, fatty acid binding protein 5 (FABP5). Without TAGLN2, FABP5 can’t do its job properly, leaving T cells famished for fats they need to function.

The scientists then pinpointed the cause of TAGLN2’s downregulation – intense stress in the cancerous environment triggers a transcription factor, XBP1, which binds and reduces TAGLN2 expression. And so, the vicious cycle of buildup: stressed T cells, impaired lipid uptake, and weakened immune response.

With the mechanism laid bare, the researchers designed a promising new therapy. They engineered chimeric antigen receptor (CAR) T cells, specific to ovarian tumor cells, to overexpress TAGLN2. In mice, these enhanced CAR T cells significantly slowed tumor growth.

O’Connor, who wasn’t affiliated with the study, praised the findings. Ovarian cancers often nestle near the fatty omentum, he noted, and this discovery helps explain how cancer cells hog nearby lipids while T cells starve.

Looking ahead, the team hopes to refine this therapy and adapt it for other challenging solid tumors. "We’re eager to see how else we can boost CAR T therapies," says Sung-Min Hwang, a coauthor on the study. Juan Cubillos-Ruiz, who led the research, envisions harnessing this knowledge for broader immunotherapeutic gains, "especially in other solid tumor types like breast or pancreatic cancer."

Despite ovarian cancer’s historic resilience, scientists are gaining ground. With each new discovery, they inch closer to helping the immune system outsmart this cunning foe.

The fight against ovarian cancer is far from over, but the tide is turning. Scientists, armed with a deeper understanding of the disease’s cunning defenses, are developing innovative strategies to outmaneuver it. This latest breakthrough, highlighting the potential of harnessing the immune system’s power, offers a beacon of hope. While challenges remain, the relentless pursuit of knowledge and collaboration within the scientific community promise brighter days ahead for ovarian cancer patients. With continued research and investment,we can move closer to a future where ovarian cancer is no longer a death sentence,but a treatable disease.
Understanding how ovarian cancer sabotages T cell function is a crucial step towards developing more effective treatments. The identification of the disrupted fat trafficking pathway offers a promising new target for intervention. By restoring T cell’s ability to utilize fat effectively, we might potentially be able to empower these immune warriors to recognise and eliminate cancerous cells more efficiently. This discovery paves the way for novel therapeutic strategies that harness the body’s own defenses to fight this tenacious disease. While ovarian cancer remains a formidable challenge, the unwavering dedication of scientists like those at Weill Cornell Medicine brings hope for a future where this deadly foe can be overcome.